QIAGEN Rallies on Takeover Talk | Quiver Quantitative

QIAGEN N.V. (QGEN) is up 6.1% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely driver is renewed takeover speculation after a market report said EQT is in advanced talks to buy QIAGEN and that the company has received a binding offer above $50 per share. A move of this size is consistent with investors repricing the stock toward a potential acquisition value, especially because QIAGEN had already been linked to strategic interest earlier this year.

Details:

A midday market update tied the jump in QGEN shares to advanced buyout discussions involving EQT, with the stock trading near a 6% gain after the report surfaced.

The same coverage indicated QIAGEN had received a binding acquisition proposal worth more than $50 per share, giving investors a concrete reference point for possible upside.

Earlier in 2026, QIAGEN was connected to fresh takeover interest from private equity groups and to broader strategic-option discussions, so today’s report appears to have revived an existing M&A theme rather than introducing a completely new idea.

QIAGEN’s own recent news flow had focused on product launches, AI-enabled bioinformatics tools, and leadership changes, which makes an acquisition-related catalyst the clearest explanation for today’s outsized move.

Sources:

Bloomberg Law, MarketScreener, QIAGEN

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

EARLY ACCESS

Receive QGEN Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$QGEN Hedge Fund Activity

We have seen 198 institutional investors add shares of $QGEN stock to their portfolio, and 153 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

PRINCIPAL FINANCIAL GROUP INC added 6,643,158 shares (+120281.7%) to their portfolio in Q2 2026, for an estimated $259,747,477
NORGES BANK added 4,325,135 shares (+inf%) to their portfolio in Q2 2026, for an estimated $169,112,778
BOSTON PARTNERS removed 3,597,424 shares (-99.2%) from their portfolio in Q2 2026, for an estimated $140,659,278
DEUTSCHE BANK AG\ removed 3,416,149 shares (-61.0%) from their portfolio in Q2 2026, for an estimated $133,571,425
MILLENNIUM MANAGEMENT LLC added 3,247,768 shares (+543.3%) to their portfolio in Q2 2026, for an estimated $126,987,728
HELIKON INVESTMENTS LTD added 3,085,155 shares (+inf%) to their portfolio in Q2 2026, for an estimated $120,629,560
GOLDMAN SACHS GROUP INC added 3,052,347 shares (+219.4%) to their portfolio in Q2 2026, for an estimated $119,346,767

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$QGEN Price Targets

Multiple analysts have issued price targets for $QGEN recently. We have seen 7 analysts offer price targets for $QGEN in the last 6 months, with a median target of $40.0.

Here are some recent targets:

Steve Beuchaw from Morgan Stanley set a target price of $42.0 on 06/23/2026
Daniel Arias from Stifel set a target price of $36.0 on 05/18/2026
Dan Brennan from TD Cowen set a target price of $40.0 on 05/07/2026
Catherine Schulte from Baird set a target price of $43.0 on 04/29/2026
Luke Sergott from Barclays set a target price of $38.0 on 04/29/2026
Patrick Donnelly from Citigroup set a target price of $38.0 on 04/29/2026
Casey Woodring from JP Morgan set a target price of $45.0 on 04/29/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.